BART Sends Bayer’s Trasylol Off The Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer “temporarily” phases out proteinase inhibitor after top-line data show 50% higher death rate for Trasylol versus comparators.
You may also be interested in...
EU's CHMP Warns About Boceprevir In HIV, Aliskiren In Diabetes, But Clears Orlistat And Reinstates Trasylol
The EU's scientific advisory panel, the CHMP, recommends prescribing information changes for drug/drug interactions with Merck's Victrelis and adverse events with Novartis' aliskiren, but clears obesity therapy orlistat of causing liver injury and reverses its 2007 negative opinion on Bayer's Trasylol.
Bayer Pulls Remaining Trasylol Supply
The anti-bleeding agent has been under an FDA-requested marketing suspension since last November.
Bayer Pulls Remaining Trasylol Supply
The anti-bleeding agent has been under an FDA-requested marketing suspension since last November.